BLAINJECTIONINJECTABLE
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REVCOVI (elapegademase-lvlr) is an intravenous enzyme replacement therapy for adenosine deaminase (ADA) deficiency, a severe combined immunodeficiency (SCID) disorder. It functions as a recombinant human adenosine deaminase enzyme that restores immune function by metabolizing toxic metabolites that accumulate in ADA-deficient patients.
$0.028BPart D
PeakThe product is in peak commercial stage with modest spending reflecting the ultra-rare patient population; commercial teams are likely maintaining specialized market access and patient support infrastructure rather than expanding field headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Registry Study of Revcovi Treatment in Patients With ADA-SCID
Started Sep 2019
32 enrolled
Adenosine Deaminase Severe Combined Immunodeficiency
Career Relevance
Working on REVCOVI offers specialists the opportunity to deepen expertise in ultra-rare disease commercialization, payer negotiations for high-cost biologics, and patient-centric access strategies. This product is ideal for professionals seeking to build differentiated skills in orphan drug marketing and health systems advocacy rather than high-volume field sales experience.
Brand Manager
Worked on REVCOVI at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.